Panmure Gordon Reiterates “Buy” Rating for Dechra Pharmaceuticals (DPH)
Dechra Pharmaceuticals (LON:DPH)‘s stock had its “buy” rating reiterated by equities research analysts at Panmure Gordon in a research note issued to investors on Tuesday, American Banking and Market News reports. They currently have a GBX 850 ($14.14) price target on the stock. Panmure Gordon’s target price would suggest a potential upside of 25.24% from the stock’s previous close.
Dechra Pharmaceuticals (LON:DPH) opened at 689.542 on Tuesday. Dechra Pharmaceuticals has a one year low of GBX 655.38 and a one year high of GBX 791.50. The stock’s 50-day moving average is GBX 699.4 and its 200-day moving average is GBX 695.1. The company’s market cap is £601.0 million.
A number of other firms have also recently commented on DPH. Analysts at Nplus1 Brewin upgraded shares of Dechra Pharmaceuticals to a “buy” rating in a research note on Tuesday. They now have a GBX 785 ($13.06) price target on the stock, up previously from GBX 740 ($12.31). Separately, analysts at N+1 Singer upgraded shares of Dechra Pharmaceuticals to a “buy” rating in a research note on Tuesday. They now have a GBX 785 ($13.06) price target on the stock, up previously from GBX 740 ($12.31). Finally, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note on Tuesday. They now have a GBX 800 ($13.30) price target on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Dechra Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of GBX 775.71 ($12.90).
Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.